|Classification and external resources|
Hypoprothrombinemia is a blood disorder in which a deficiency of prothrombin (Factor II) results in impaired blood clotting, leading to an increased physiological risk for bleeding, especially in the gastrointestinal system, cranial vault, and superficial integumentary system.
Hypoprothrombinemia can be the result of a genetic defect, may be acquired as the result of another disease process, or may be an adverse effect of medication. For example, 5-10% of patients with systemic lupus erythematosus exhibit acquired hypoprothrombinemia due to the presence of autoantibodies which bind to prothrombin and remove it from the bloodstream (lupus anticoagulant-hypoprothrombinaemia syndrome).
Hypoprothrombinemia can be treated with periodic infusions of purified prothrombin complexes.
- A known treatment for hypoprothrombinemia is menadoxime.
- Menatetrenone was also listed as a Antihaemorrhagic vitamin.
- 4-Amino-2-methyl-1-naphthol (Vitamin K5) is another treatment for hypoprothrombinemia.
- Bajaj S, Rapaport S, Fierer D, Herbst K, Schwartz D (1983). "A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome.". Blood. 61 (4): 684–92. PMID 6403077.
- [ http://www.gene.com/download/pdf/rocephin_prescribing.pdf Rocephin proscribing information]. Accessed October 24, 2013.
- Lechler E (1999). "Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z.". Thromb Res. 95 (4 Suppl 1): S39–50. PMID 10499908. doi:10.1016/S0049-3848(99)00083-3.
- J. Elks, C. R. Ganellin · DoDs page 765.
|This article about a disease of the blood or immune system is a stub. You can help Wikipedia by expanding it.|